一分钟看懂
这是一项关于急性髓系白血病的II 期研究，登记的药物或干预包括Quizartinib High Dose；Quizartinib Low Dose，当前状态为招募中。登记地点显示中国北京、长春、广州、杭州等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Quizartinib High Dose；Quizartinib Low Dose · II 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Peking Union Medical College Hospital · 北京
- Peking University Third Hospital · 北京
- The First Hospital of Jilin University · 长春
- Guangdong Provincial People's Hospital · 广州
- Nanfang Hospital of Southern Medical University · 广州
- Sun Yat-sen University Cancer center · 广州
- The First Affiliated Hosptial of Zhejiang University School of Medicine · 杭州
- The First Affiliated Hospital of Nanchang University · 南昌
- Zhong Da Hospital, Southeast University · 南京
- The First Affiliated Hospital of Guangxi Medical University · 南宁
- The Affiliated Hospital of Qingdao University · 青岛
- Huashan Hospital, Fudan University · 上海
- The First Affiliated Hospital of Soochow University · 苏州
- Hematology Hospital of the Chinese Academy of Medical Sciences · 天津
- The First Affiliated Hospital of Wenzhou Medical University · 温州
- The First Affiliated Hospital of Jiaotong University · 西安
- The First Affiliated Hospital of Xiamen University · 厦门
- The Affiliated Hospital of Xuzhou Medical College · 徐州
- The First Affiliated Hospital of Zhengzhou University · 郑州
公开的入选条件
- 1. Adults ≥18 years of age or the minimum legal adult age (whichever is greater) on the day of signing the ICF (no upper limit of age).
- 2. Newly diagnosed, morphologically documented primary AML or AML secondary to myelodysplastic syndrome or a myeloproliferative neoplasm based on the World Health Organization (WHO) 2008/2016 classification.
- 3. Participant has confirmed FLT3-ITD-positive (≥0.05 SR or ≥5% VAF) activating mutation from initial diagnosis in bone marrow or peripheral blood as determined by a local institution's validated molecular testing.
- 4. Participants must have confirmed, morphologically documented CR1, on the most recent BMA, based on the local laboratory results, performed within 28 days prior to C1D1 of maintenance therapy. Complete remission will be defined as \<5% blasts in the bone mar
- Complete blood count recovery is required with absolute neutrophil count of more than 1.000 × 109/L and platelets more than 100 × 109/L (IWG criteria).27
- 5. Participant must meet the following prior therapy requirements:
- 1. Has received at least one cycle of induction therapy but no more than two to achieve CR1. The induction cycles can be the same regimen or different regimens and may contain conventional agents only (e.g., cytarabine + daunorubicin or idarubicin: "7 + 3" or
- 2. Has not received more than four cycles of consolidation therapy. Regimens may contain conventional agents only.
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT06824168；登记信息更新于 2026-09-16。